Yazar "Boyunağa H." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Alteration of tumor glucose metabolism after radiotherapy in MCF-7 breast cancer cell lines
    (UHOD - Uluslararasi Hematoloji Onkoloji Dergisi, 2006) Cengiz M.; Boyunağa H.; Yildiz F.; Ural A.U.; Atahan I.L.
    Cancer cells utilize anaerobic glycolytic way to compensate their faster metabolism when compared to normal cells. The purpose of this study is to investigate the effect of radiation on tumor metabolism. MCF-7 breast cancer cell lines were divided into 4 groups, including 2 control groups and aerobic and anaerobic study groups (were irradiated 600 cGy by Co-60 teletherapy unit), incubated with radiolabelled glucose for 4 hours. One control group was for aerobic, and the other was for anaerobic group after KCN addition. Radiolabelled CO2 produced by the cells was isolated and collected in specially designed simulation vials. In supernatant the measurements of other end-products of carbohydrate catabolism including lactate, pyruvate, acetate were performed on a liquid scintillation analyzer after they were collected via anion-exchange chromatography. Finally glucose in supernatant was measured enzymatically by glucose oxidase method. Glycogen consumption and lactate production were significantly higher in anaerobic and radiation groups (p<0.01). Whereas CO2 production was significantly higher in control group (p<0.01). Taken all results together radiation lead tumor cells more anaerobic glycolysis with high glycogen consumption, high lactate production and low CO2 production. Radiation itself has led tumor cells to produce energy by anaerobic glycolysis, meaning radiation exposed cells become more hypoxic.
  • Küçük Resim
    Öğe
    The effects of Ara-C, simvastatin and combo therapy on energy metabolism of HL-60 promyolocytic leukemia cell lines
    (Turkish Biochemistry Society, 2013) Boyunağa H.; Günnur Dikmen Z.; Kenar L.; Saygun O.; Keleş H.; Ugur Ural A.; Lale M.
    Objective: Cancer cells choose their metabolic pathway depending on the oxygen content and substrate concentration of the medium. A wide spectrum of therapeutic agents regulating the energy metabolism of cancer cells are in still in use. Cytosine arabinoside (Ara-C) is a pyrimidine analogue used in the treatment of acute myeloid leukemia (AML) and simvastatin is an inhibitor of HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase, which regulates cholesterol biosynthesis. Thus, this study aimed to assess the energy metabolism of HL-60 promyelocytic leukemia cells and healthy white blood cells, additionally to determine the effects of simvastatin and Ara-C, alone or in combination on the energy metabolism of these cells. Materials and Methods: Healthy white blood cells, untreated and treated HL-60 promyolocytic leukemia cell lines were incubated for 4 hours with radiolabelled glucose. Following incubation, lactate, which is one of the end products of the carbohydrate catabolism, and radiolabelled CO2 produced by cells were collected and measured by the liquid scintillation device. In addition, glycogen consumption per hour was determined in each group. Results and Conclusion: We found that untreated HL-60 promyolocytic cells use anaerobic glycolytic pathway whereas healthy white blood cells use aerobic glycolysis for energy gain. It was concluded that combined use of Ara-C and Simvastatin might lead to significant increase in the rate of aerobic glycolysis of HL-60 promyelocytic cells and the metabolism of these leukemia cells become more similar to the metabolism of healthy white blood cells which they originate from. © TurkJBiochem.com.